Q.1
For a patient with castration-sensitive prostate cancer and high volume metastatic disease, which of the following first-line therapies would you recommend?
ADT alone
ADT + docetaxel
Q.2
When you prescribe an AR pathway targeted agent for mCRPC, which one would you use first?
Abiraterone first
Enzalutamide first
It doesn’t matter
Q.3
Do you think there is cross-resistance between approved AR pathway targeted agents (abiraterone and enzalutamide)?
Yes
No
Uncertain
Q.4
Which aspect of the phase III ALSYMPCA trial of Ra-223 for patients with mCRPC and bone metastases do you find most compelling?
Adverse events including myelosuppression were mild and manageable
A statistically significant survival advantage was seen
The study population accurately represented the general population of patients with mCRPC
The nonoverlapping mechanism of action of Ra-223 makes it a good candidate for either sequential or concomitant use with other available therapies for mCRPC
Q.5
Have you had the opportunity to prescribe Ra-223 for a patient with mCRPC in your practice?
Yes
No